Literature DB >> 11376560

Urokinase receptor and vascular endothelial growth factor are synergistically associated with the liver metastasis of colorectal cancer.

H Konno1, J Abe, T Kaneko, M Baba, A Shoji, K Sunayama, K Kamiya, T Tanaka, S Suzuki, S Nakamura, T Urano.   

Abstract

Considering recent findings that the urokinase plasminogen activation (PA) system is involved in invasion and vascular endothelial growth factor (VEGF) is involved in angiogenesis of colorectal cancer, we evaluated these factors in the liver metastasis of primary colorectal cancer. Cancer tissues from 71 colorectal cancer patients were assayed quantitatively for antigen levels of urokinase type plasminogen activator (uPA), uPA receptor (uPAR), and plasminogen activator inhibitor-1 and -2 (PAI-1, PAI-2), and were also assayed immunohistochemically for expression of VEGF protein. Among the PA system factors, both the levels of uPAR and PAI-1 were significantly higher in larger tumors than in smaller ones, and were also significantly higher in tumors that invaded subserosa, serosa or adjacent organs than in mucosal, submucosal tumors or in tumors that invaded the muscle layer. The uPAR levels were significantly higher in tumors with liver metastasis than in those without. VEGF overexpression was significantly more frequent in tumors with lymph node involvement or liver metastasis than in those without. Among the PA system factors, the uPAR levels were significantly higher in tumors with VEGF overexpression and a multivariate analysis revealed that high uPA level and VEGF overexpression were independent risk factors for liver metastasis. The combination of high uPAR level and overexpression of VEGF was associated with the worst prognosis in patients with colorectal cancer. These results suggest that uPAR and VEGF might contribute synergistically to the liver metastasis of colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11376560      PMCID: PMC5926736          DOI: 10.1111/j.1349-7006.2001.tb01124.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  46 in total

1.  Involvement of vascular endothelial growth factor and urokinase-type plasminogen activator receptor in microvessel invasion in human colorectal cancers.

Authors:  S Nakata; K Ito; M Fujimori; K Shingu; S Kajikawa; W Adachi; I Matsuyama; S Tsuchiya; M Kuwano; J Amano
Journal:  Int J Cancer       Date:  1998-04-17       Impact factor: 7.396

2.  Overexpression of vascular endothelial growth factor is responsible for the hematogenous recurrence of early-stage gastric carcinoma.

Authors:  H Konno; M Baba; T Tanaka; K Kamiya; M Ota; K Oba; A Shoji; T Kaneko; S Nakamura
Journal:  Eur Surg Res       Date:  2000       Impact factor: 1.745

3.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer.

Authors:  M J Duffy; D Reilly; C O'Sullivan; N O'Higgins; J J Fennelly; P Andreasen
Journal:  Cancer Res       Date:  1990-11-01       Impact factor: 12.701

4.  Anti-angiogenesis: new concept for therapy of solid tumors.

Authors:  J Folkman
Journal:  Ann Surg       Date:  1972-03       Impact factor: 12.969

5.  Resection of hepatic metastases of colorectal carcinoma: 20 years' experience.

Authors:  S Nakamura; S Suzuki; H Konno
Journal:  J Hepatobiliary Pancreat Surg       Date:  1999

6.  Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer.

Authors:  H E Mulcahy; M J Duffy; D Gibbons; P McCarthy; N A Parfrey; D P O'Donoghue; K Sheahan
Journal:  Lancet       Date:  1994-08-27       Impact factor: 79.321

7.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.

Authors:  Y Takahashi; Y Kitadai; C D Bucana; K R Cleary; L M Ellis
Journal:  Cancer Res       Date:  1995-09-15       Impact factor: 12.701

8.  Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells.

Authors:  S J Mandriota; G Seghezzi; J D Vassalli; N Ferrara; S Wasi; R Mazzieri; P Mignatti; M S Pepper
Journal:  J Biol Chem       Date:  1995-04-28       Impact factor: 5.157

9.  Quantitative analysis of vascular endothelial growth factor in primary breast cancer.

Authors:  M Toi; S Kondo; H Suzuki; Y Yamamoto; K Inada; T Imazawa; T Taniguchi; T Tominaga
Journal:  Cancer       Date:  1996-03-15       Impact factor: 6.860

10.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?

Authors:  G Deng; S A Curriden; S Wang; S Rosenberg; D J Loskutoff
Journal:  J Cell Biol       Date:  1996-09       Impact factor: 10.539

View more
  5 in total

1.  Cyclooxygenase-2 expression correlates with uPAR levels and is responsible for poor prognosis of colorectal cancer.

Authors:  Hiroyuki Konno; Megumi Baba; Tuyoshi Shoji; Manabu Ohta; Shohati Suzuki; Satoshi Nakamura
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

2.  Relationship between urokinase-type plasminogen activator receptor and vascular endothelial growth factor expression and metastasis of gallbladder cancer.

Authors:  Shu-Qiang Yue; Yan-Ling Yang; Jing-Shi Zhou; Kai-Zong Li; Ke-Feng Dou
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

3.  Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.

Authors:  Diana L Hanna; Fotios Loupakis; Dongyun Yang; Chiara Cremolini; Marta Schirripa; Meng Li; Satoshi Matsusaka; Martin D Berger; Yuji Miyamoto; Wu Zhang; Yan Ning; Carlotta Antoniotti; Lisa Salvatore; Miriana Moran; Gary Zeger; Stephanie H Astrow; Alfredo Falcone; Heinz-Josef Lenz
Journal:  Clin Colorectal Cancer       Date:  2018-03-14       Impact factor: 4.481

4.  Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer.

Authors:  A F Lomholt; G Høyer-Hansen; H J Nielsen; I J Christensen
Journal:  Br J Cancer       Date:  2009-08-11       Impact factor: 7.640

5.  High concentration of urokinase-type plasminogen activator receptor in the serum of women with primary breast cancer.

Authors:  Anna Thielemann; Aleksandra Baszczuk; Przemysław Kopczyński; Zygmunt Kopczyński
Journal:  Contemp Oncol (Pozn)       Date:  2013-11-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.